Â鶹ŮÓÅ

A study of US adults who had community-acquired pneumonia (CAP) but were otherwise healthy found that broad-spectrum antibiotics were associated with increased risks of adverse drug events (ADEs), researchers reported yesterday in Clinical Infectious Diseases. (Dall, 10/24)

The adjuvanted influenza and adjuvanted shingles vaccines can be safely administered at the same time, a randomized, blinded clinical trial concludes. Duke University investigators compared the safety of and reactions to simultaneous intramuscular vaccination with the quadrivalent (four-strain) inactivated adjuvanted flu vaccine (allV4) and the adjuvanted recombinant herpes zoster (shingles) vaccine (RSV) with that of simultaneous administration of the RZV and quadrivalent high-dose inactivated nonadjuvanted flu vaccine (HD-IIV4) vaccines. (Van Beusekom, 10/24)

New genomic surveillance data published today in Morbidity and Mortality Weekly Report show that JN.1 and its descendants have been the most common SARS-CoV-2 variants in 2024, and they're still evolving. The genomic surveillance was conducted by the Centers for Disease Control and Prevention's national SARS-CoV-2 genomic surveillance program, which previously detected both the Delta and Omicron variants. (Soucheray, 10/24)

The diabetes and weight loss drug Ozempic could lower the risk of Alzheimer’s disease among people with Type 2 diabetes, according to a new study published Thursday. Alzheimer’s disease is the seventh-leading cause of death in the United States, with roughly 120,000 people dying from the disease each year, according to data from the Centers for Disease Control and Prevention. (O’Connell-Domenech, 10/24)

Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes, an analysis of medical records found, supporting the case for further research of the blockbuster GLP-1 drug in neurodegenerative diseases. (Chen, 10/24)